Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Matrix Biol. 2016 Mar 22;55:22–34. doi: 10.1016/j.matbio.2016.03.006

Figure 1.

Figure 1

Anti-myeloma therapy elevates heparanase expression. (A) Heparanase protein was assessed by western blotting of total cell extracts from different myeloma cell lines after 14 h treatment with BTZ (25 nM), Dex (10 μM) or Doxorubicin (Dox, 5 μM). At these concentrations the drugs inhibited cell proliferation to a similar extent. Untreated cells served as controls. GAPDH is the loading control. (B) Heparanase transcript level in myeloma cells was assessed by real time PCR after 8 h treatment with BTZ (50 nM), CFZ (100 nM), Mel (20 μM). Transcript levels in vehicle treated cells served as control, *p<0.05 versus vehicle treated cells. (C) HPSE protein levels as revealed by western blotting after treatment with BTZ (25 nM) alone for 14 h or with BTZ after 2 h pretreatment with cycloheximide (CHX, 30 μg/ml).

HHS Vulnerability Disclosure